The Pentagon is temporarily rescinding recently published clinical guidance for a new mandatory testosterone-deficiency screening policy, Reuters reports.
After years of a Patriot monopoly, new anti-ballistic alternatives are emerging. Officials hope to see some of them on the battlefield by the end of 2026.
